menu

Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine.

Facebook Comments

Schedule25 May 2024